InterPAD - DETAILS

10-Hydroxycamptothecin, 19685-09-7, (S)-10-Hydroxycamptothecin, Hydroxycamptothecin, 10-hydroxycamptothecine, 10-Hydroxy camptothecin, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, Hydroxycamptothecine, (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, Camptothecin, hydroxy-, Camptothecine, 10-hydroxy-, 10-HCPT, 10-Hydroxy-Camptothecin, NSC107124, NSC-107124, CHEMBL273862, CHEBI:81395, 9Z01632KRV, Hydroxy camptothecine, MFCD02093100, (S)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione, Camptothecin, 10-hydroxy-, (20S)-4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione ((S)-10-Hydroxycamptothecin), NSC 107124, (S)-10-Hydroxycamptothecin hydrate, UNII-9Z01632KRV, CAMPTOTHECIN, 10-HYDROXY, 10-Hydroxy-CPT, Spectrum_001639, (+)-(S)-10-HYDROXYCAMPTOTHECIN, SpecPlus_000763, Spectrum2_001660, Spectrum3_001621, Spectrum4_001815, Spectrum5_000549, ethyl(dihydroxy)[?]dione, SCHEMBL25875, BSPBio_003281, KBioGR_002454, KBioSS_002119, 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4,9-dihydroxy-, hydrate, (S)-, DivK1c_006859, SPECTRUM1504123, SPBio_001819, KBio1_001803, KBio2_002119, KBio2_004687, KBio2_007255, KBio3_002501, DTXSID00941444, EX-A988, BCP01385, HY-N0095, (+)-10-HYDROXYCAMPTOTHECIN, BDBM50008922, CCG-38770, s2423, s3898, AKOS015919293, AC-5502, BCP9000058, CS-5193, DB12385, 10-HYDROXYCAMPTOTHECIN [WHO-DD], NCGC00095986-01, NCGC00095986-02, NCGC00095986-03, NCGC00095986-04, NCGC00178165-01, 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-, AC-13221, AS-13196, NCI60_000173, SY010687, FT-0607192, FT-0689364, H1463, NS00018317, A25382, C17939, EN300-19810684, SR-05000002620, Q-100241, SR-05000002620-1, BRD-K63784565-001-02-1, BRD-K63784565-001-03-9, Q27155328, Z3093896188, 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione, (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione, (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione, (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, (S)-10-Hydroxycamptothecin;-;(+/-)-4-ethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione, 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4-ETHYL-4,9-DIHYDROXY-, (4S)-, 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-, 4-Ethyl-4,10-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione, 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (10-hydroxycamptothecin)

Name	Hydroxycamptothecin
PubChem CID	97226
Molecular Weight	364.4g/mol
Synonyms	10-Hydroxycamptothecin, 19685-09-7, (S)-10-Hydroxycamptothecin, Hydroxycamptothecin, 10-hydroxycamptothecine, 10-Hydroxy camptothecin, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, Hydroxycamptothecine, (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, Camptothecin, hydroxy-, Camptothecine, 10-hydroxy-, 10-HCPT, 10-Hydroxy-Camptothecin, NSC107124, NSC-107124, CHEMBL273862, CHEBI:81395, 9Z01632KRV, Hydroxy camptothecine, MFCD02093100, (S)-4-ethyl-4,9-dihydroxy-1,12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione, Camptothecin, 10-hydroxy-, (20S)-4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione ((S)-10-Hydroxycamptothecin), NSC 107124, (S)-10-Hydroxycamptothecin hydrate, UNII-9Z01632KRV, CAMPTOTHECIN, 10-HYDROXY, 10-Hydroxy-CPT, Spectrum_001639, (+)-(S)-10-HYDROXYCAMPTOTHECIN, SpecPlus_000763, Spectrum2_001660, Spectrum3_001621, Spectrum4_001815, Spectrum5_000549, ethyl(dihydroxy)[?]dione, SCHEMBL25875, BSPBio_003281, KBioGR_002454, KBioSS_002119, 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4,9-dihydroxy-, hydrate, (S)-, DivK1c_006859, SPECTRUM1504123, SPBio_001819, KBio1_001803, KBio2_002119, KBio2_004687, KBio2_007255, KBio3_002501, DTXSID00941444, EX-A988, BCP01385, HY-N0095, (+)-10-HYDROXYCAMPTOTHECIN, BDBM50008922, CCG-38770, s2423, s3898, AKOS015919293, AC-5502, BCP9000058, CS-5193, DB12385, 10-HYDROXYCAMPTOTHECIN [WHO-DD], NCGC00095986-01, NCGC00095986-02, NCGC00095986-03, NCGC00095986-04, NCGC00178165-01, 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-, AC-13221, AS-13196, NCI60_000173, SY010687, FT-0607192, FT-0689364, H1463, NS00018317, A25382, C17939, EN300-19810684, SR-05000002620, Q-100241, SR-05000002620-1, BRD-K63784565-001-02-1, BRD-K63784565-001-03-9, Q27155328, Z3093896188, 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione, (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione, (19S)-19-ethyl-7,19-dihydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione, (4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, (S)-10-Hydroxycamptothecin;-;(+/-)-4-ethyl-4,9-dihydroxy-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione, (S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione, 1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE, 4-ETHYL-4,9-DIHYDROXY-, (4S)-, 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione-,4-ethyl-4,9-dihydroxy-, (S)-, 4-Ethyl-4,10-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione, 4-Ethyl-4,9-dihydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (10-hydroxycamptothecin)
Drug Type	Small molecule
Formula	C₂₀H₁₆N₂O₅
SMILES	CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C3=C2)N=C5C=CC(=CC5=C4)O)O
InChI	1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3/t20-/m0/s1
InChIKey	HAWSQZCWOQZXHI-FQEVSTJZSA-N
CAS Number	19685-09-7
ChEMBL ID	CHEMBL273862
ChEBI ID	CHEBI:81395
TTD ID	D07ILP
Drug Bank ID	DB12385
KEGG ID	C17939
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Bufalin, Hydroxycamptothecin
Partner Name	Bufalin
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL-xL	hsa598
	Up-regulation	Expression	GSK3B	hsa2932
	Up-regulation	Expression	PDCD4	hsa27250
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	DU145	Prostate carcinoma	Homo sapiens (Human)	CVCL_0105
In Vivo Model	Cell suspensions of DU 145 cells in the logarithmic growth phase were prepared at a concentration of 1×10⁷ cells/ml, using physiological saline.
Result	The present study suggested that the combination of bufalin and hydroxycampothecin improved the inhibitory effects of both drugs on CRPC tumors in vivo, potentially via the regulation of the PI3K/AKT/GSK-3β and p53-dependent apoptosis signaling pathways.